Compare HCA Health Inc (HCA) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Xylem, Inc. — how do they compare? HCA Health Inc trades at $410.1 (market cap $89.08B), while Xylem, Inc. trades at $120.88 (market cap $28.76B). The key difference: HCA Health Inc is far larger — about 3.1× Xylem, Inc.'s market cap, and Xylem, Inc. pays the higher dividend (1.4%). Which is the better fit depends on your goals.
| HCA | XYL | |
|---|---|---|
Market Cap | $89.08B | $28.76B |
Sector | Health | Industrials |
52-Week High | $545.13 | $152.95 |
52-Week Low | $361.32 | $106.34 |
Enterprise Value | $139.62B | $30.54B |
Dividend Yield | 0.76% | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $414.03, up 0.16% today, with strong technical momentum as price sits above key support levels. The company demonstrates solid fundamentals with Q2 2026 earnings beating estimates, revenue growth to $75.6B in 2025, and consistent dividend payments. Recent management appointments signal strategic focus on clinical operations and ambulatory services.
HCA presents a compelling investment case with attractive valuation (P/E 13.8), analyst consensus price target of $449.93 (8.7% upside), and strong institutional support. However, risks include ongoing legal investigations, rising expenses impacting margins, and high debt levels at 80.9% debt-to-asset ratio that could constrain financial flexibility.
Xylem (XYL) trades at $121.19, up 0.72% today, with a bullish technical trend and strong fundamental performance. The company reported Q2 2026 EPS of $1.46, beating estimates, and raised full-year profit guidance. Revenue growth is steady, with a net income margin of 11.15% in 2025. Recent acquisitions, like Cornell Pump and Roper Pump, aim to strengthen its industrial water technology presence. The stock shows bullish moving averages but a neutral RSI, with key resistance at $123.
Outlook remains positive due to earnings beats, margin expansion, and strategic acquisitions. Risks include execution of integration and macroeconomic pressures. Analyst consensus is a buy with a $150.43 price target, implying significant upside. Institutional activity is mixed, with some funds increasing stakes while others reduced holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
